BACKGROUND Poor adherence to medication regimens is common, potentially contributing to the occurrence of
R esponsible for 12% of all deaths worldwide, stroke is the second leading cause of mortality after ischemic heart disease (1) . Despite a decline of 20% in age-standardized stroke mortality rates from 1990 to 2013, the number of stroke deaths has increased by 40% (2) . Moreover, stroke accounted for a total of 66.4 million disability-adjusted life years in people aged 60 years or older in 2010, and this burden of disease is predicted to increase by 44% from 2004 to 2030 (3, 4) .
High blood pressure and high cholesterol concentration are key risk factors for stroke for which effective pharmacological therapies are available.
Evidence from trials suggest that statin treatment reduces stroke risk by between 15% and 25%, irrespective of the patient's baseline cardiovascular disease risk (5, 6) . For stroke prevention, the benefits of antihypertensive medication are of similar magnitude to those seen for statins, such that a 15% to 25% decrease in 5-year stroke risk is apparent, irrespective of baseline stroke risk (7) . Stroke rates also appear to decline in proportion to the reduction in cholesterol and blood pressure (6, 8) .
In clinical settings, a major obstacle for the full benefits of lipid-lowering and antihypertensive treatments is the nonadherence of patients to drug therapy (9) (10) (11) ; that is, a failure to take their medications as prescribed by their physician. At least 3 studies have shown a significantly increased risk of stroke in hypertensive patients who do not adhere to their antihypertensive treatment regimens relative to those who are more compliant (9) (10) (11) . Few studies have examined the effects of nonadherence to statin use on stroke risk, however, and we are aware of no studies that have quantified the extent to which nonadherence to statin therapy is associated with stroke risk among hypercholesterolemia patients with hypertension.
In the present study, we used records from nationwide drug prescription, hospitalization, and death registers to determine the risk of fatal stroke associated with nonadherence to statin therapy among hypercholesterolemia patients. In addition, we examined the risk of fatal stroke associated with nonadherence to statin therapy, antihypertension therapy, or both among hypercholesterolemia patients with a hypertension diagnosis. (14) . To examine dose-response association, we used the adherence thresholds of <30% (poor adherence), 30% to 80% (intermediate 
Herttua et al. Table 1 . Cases (i.e., those who died from stroke) were older and less educated than controls. Moreover, the cases were more often diagnosed with diabetes or cancer. Of the stroke deaths as the first presentation of the disease, 36% (n ¼ 190) were ischemic, 32% (n ¼ 168) hemorrhagic, 16% (n ¼ 86) subarachnoid hemorrhage, and 16% (n ¼ 88) other types.
ANALYSIS OF STROKE RISK ASSOCIATED WITH
NONADHERENCE TO STATIN THERAPY. The proportion of adherence to statins was 58% in men and 60% in women. The corresponding proportion was 52% for those age <57 years, 60% for those age 57 to 65 years, 63% for those age 66 to 72 years, and 61% for those age >72 years (data not shown). Figure 2 shows results from the association between adherence to statin therapy and fatal stroke assessed Herttua et al. 
ANALYSIS OF DOSE-RESPONSE ASSOCIATION.
Complementary models (Online Table 1 Odds ratios (ORs) are adjusted for age, sex, diabetes mellitus, and history of cancer.
CI ¼ confidence interval.
Herttua et al. Herttua et al. separately that indicated lower adherence to these therapies is associated with a higher risk of stroke or other cardiovascular events (10, 11, 15) . We have previously found that patients nonadherent to antihypertensive medication had 5.7 (95% CI: 5.1 to 6.4) times higher odds of stroke death when compared with adherent patients in the last year of life (11) .
Results from an Italian study reported that, when compared with patients with poor adherence, patients with good or excellent adherence to antihypertensive medication had a 30% to 50% lower risk for a composite outcome of all-cause mortality, fatal or nonfatal stroke, and fatal or nonfatal acute myocardial infarction, although separate analyses for the stroke outcomes indicated no statistically significant differences between the adherence groups (10). 
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